Clinical trial
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive…
NCT00224484 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00224484 |
|---|---|
| Title | Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old |
| Official title | A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2-AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Herpes Simplex |
| Intervention type | Biological |
| Interventions | GSK208141, Havrix (investigational formulation), Placebo |
| Enrollment | 5,960 |
| Start date | Apr 7, 2004 |
| Primary completion | Jul 24, 2007 |
| Completion | Jul 24, 2007 |
| First posted | Sep 23, 2005 |
| Last update posted | Jan 7, 2019 |
| Countries | Australia, Belgium, Canada, Denmark, Estonia, France, Greece, Hungary, Iceland, Lithuania, Netherlands, New Zealand and 6 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: